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The antibodies that are produced in man as a result of specific vaccination or 
infectious  disease  comprise  only  a  small  proportion  of  the  bulk  of  the  IgG 
molecules  circulating  in  the  blood.  The  immunity  towards  these  antigens  is 
attributed mostly to a relatively high number of memory cells and a low titer of 
synthesized antibodies. In view of kinetic studies of antibody production and the 
low level of IgG in  the serum  of germ-free animals,  it is safe to assume  that a 
large  proportion  of circulating  IgG  molecules  are  synthesized  as  a  result  of 
immune reactivity to naturally occurring antigens, to which the immune system 
is constantly exposed.  Most of the  known high-titer natural antibodies seem to 
display anticarbohydrate specificity. These include the anti-blood group A  and 
B antibodies, which interact with GalNAc~I ~  3(Fuco~l ~  2)Gal and Galal 
3[Fucal ~  2]Gal (GalNAc, N-acetyl gatactose; Fuc, fucose)  1, respectively (1, 2). 
Another natural antibody with anticarbohydrate specificity is the anti-T (Thom- 
sen-Friedenreich) antibody, which binds to Gal/31  ~  4GalNAc residues (3, 4). It 
is assumed that these anticarbohydrate antibodies are constantly produced as an 
immune  response  to  normal  gastrointestinal  or  pulmonary  flora  that  contain 
bacteria bearing such antigenic epitopes (1, 3). 
We  have  recently  (5-7)  described  a  natural  IgG  antibody  that  appears  to 
contribute to extravascular lysis of normal and some pathological red cells, since 
it  interacts  in  situ  with  normal  senescent  red  cells and  more  extensively with 
pathological red cells of thalassemia and sickle cell anemia patients. This antibody, 
designated anti-Gal, was found in high titer in all normal sera tested, independent 
of blood  type.  Furthermore,  it  represents  1%  of the  total  serum  IgG.  The 
reactivity ofanti-Gal could be assessed by its interaction with c~-galactosyl residues 
on  rabbit  red  blood cells (RRBC)  (8).  To evaluate  the structure of the  RRBC 
antigen  recognized  by anti-Gai,  we  have  studied  its  binding  to  carbohydrate- 
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containing molecules isolated from these cells.  We have found that anti-Gal has 
a binding specificity for glycosphingolipids with an o~1 ~  3 nonreducing terminal 
galactose,  but  does not  bind  to a  RRBC  glycosphingolipid  with a  nonreducing 
terminal a 1 --+ 4  galactose. In addition  to obtaining a  more complete character- 
ization  of the  binding  specificity of this  unique  natural  antibody,  these  studies 
may shed light on the  nature  of the antigenic  epitope exposed on human  RBC 
upon normal and pathological senescence. 
Materials and  Methods 
RRBC  and  Ghosts.  Rabbits were bled  from the  marginal  ear  vein.  The  blood  was 
collected in heparinized tubes. The RRBC were washed five times in phosphate-buffered 
saline (PBS) to remove the plasma and buffy coat. RRBC ghosts were prepared according 
to the method of Dodge et al.  (9).  Packed, washed RRBC were resuspended in  80  vol 
lysing buffer and incubated on ice for 15-30 rain. The lysing buffer (pH 7.4) contained 
5  mM  Tris,  7  mM  KCI, and  1 mM  diisopropyl  fluorophosphate  to  suppress  protease 
activity. Hemoglobin was removed from the erythrocyte membrane by repeated washings 
with PBS. 
Oligosaccharides.  Melibiose,  a-methyl galactoside,  lactose,  and  B-methyl  galactoside 
were  purchased  from  Sigma  Chemical  Co.  (St.  Louis,  MO).  The  oligosaccharides 
Galc~l  --+ 3Gal,  Galcd  ~  4Gal,  and  Galcd  ~  4Gal/31 --+ 4GlcNAc (GlcNAc, N-acetyl 
glucose) were kindly provided by Dr.  Don  Baker (Chem Biomed,  Edmonton,  Canada, 
supplied as the 0(CH2)8C02 methylglycosides). 
Isolation  of Anti-Galfrom Normal Serum.  The method for purifying this natural anti- 
body from normal AB serum was described previously (5).  Briefly, batches of 100 ml of 
AB  heat-inactivated  serum  or  plasma  were  loaded  at  37°C  onto  a  10  ml  melibiose- 
Sepharose  column  (Sigma  Chemical  Co.)  bearing  terminal  c~-galactosyl  residues.  The 
antibodies retained on the column after extensive washing were eluted by 0.5 M melibiose. 
The carbohydrate was removed by repeated dialysis against large volumes of PBS,  and 
the anti-Gal IgG molecules were concentrated to a volume of 5 ml using a protein A- 
Sepharose  column  (Sigma  Chemical  Co.).  As  an  optional  column,  the  Synsorb  a-gal 
column (Chem Biomed) was used.  To remove any residual anti-T activity, the anti-Gal 
was absorbed on neuraminidase-treated RBC. The anti-Gal reactivity was determined by 
the binding of the purified antibody to RRBC, as assessed by agglutination. The anti-Gal 
preparations used in the present study agglutinated the RRBC up to a titer of 1:512. 
Isolation  of RRBC Glycosphingolipids.  RRBC glycosphingolipids were prepared as fol- 
lows:  A total lipid extract was obtained by extracting ghosts with chloroform/methanol 
mixtures (2:1,  1:1,  1:2)  (vol/vol) at  room temperature  for  20  rain  each  (10).  Neutral 
glycosphingolipids were separated from gangliosides and phospholipids by DEAE-Sepha- 
dex column chromatography (11).  Subfractionation of the neutral glycosphingolipids was 
done by high-performance liquid chromatography (HPLC) using an Iatrobeads column 
(1  x  50 cm; 6RS-8010;  Iatron Chemical Products, Tokyo, Japan), and a linear gradient 
of isopropyl alcohol/hexane/water  (55:44:1-55:35:10)  at  2  ml/min (12).  The gradient 
was  completed  in  30  min,  and  the  fractionation  was  continued  for  20  min  with  the 
55:35:10  solvent  mixture.  Fractions  containing  ceramide  pentahexoside  (CPH)  were 
pooled and rechromatographed on a small (4.6 mm X 25 cm) Iatrobead column using the 
same gradient solvent system. Glycosphingolipids were separated by thin-layer chroma- 
tography on Silica Gel 60, high-performance thin-layer chromatography (HPTLC) plates, 
using chloroform/methanol/water (60:35:8)  (vol/vol), and stained with orcinol reagent. 
Standard  glycosphingolipids  were  either  obtained  from  Supelco  (Bellefonte,  PA)  or 
prepared from human leukocytes, as previously described (10). The human B glycosphin- 
golipid was kindly provided by Dr. Ten Feizi (Clinical Research Centre, Harrow, United 
Kingdom). 
Immunostaining of Glycosphingolipids.  Immunostaining of glycosphingolipids was done 
on aluminum-backed plates of Silica  Gel 60  (plates 5538;  E.  Merck Laboratories, Inc., GALILI ET  AL.  575 
Cincinnati, OH). Glycosphingolipids were chromatographed in the solvent mixture chlo- 
roform/methanol/water (60:35:8). After drying, the plate was dipped (20 sec) in a solution 
of 0.05% polyisobutylmethylacrylate (Polyscience, Inc., Warrington,  PA) in hexane, and 
air dried. The plate was soaked as follows: 30 min in PBS with 5% bovine serum albumin 
(BSA), 2 h in the primary antibody (anti-Gal) diluted  1:500 with PBS and 1% BSA, 2 h at 
room temperature  in  a  secondary antibody (rabbit  anti-human  IgG; Ortho  Immunodi- 
agnostics,  Raritan,  NJ)  diluted  1:500  with  PBS  and  1%  BSA,  and  for  2  h  at  room 
temperature  in  a  solution  of 125I-protein A  (New  England  Nuclear,  Boston,  MA) (106 
cpm/ml  in  PBS with  1%  BSA). The plate  was washed with  normal saline  solution  five 
times  between  each  incubation  step.  Finally,  it  was dried,  and  an  autoradiograph  was 
prepared (Kodak X-O-mat AR2, 24-48 h at -20°C). 
Glycosidase Treatment  of Glycosphingolipids.  Glycosphingolipids were hydrolyzed with 
~-galactosidase  purified  from  Ficin  (13).  The  reaction  mixture  contained  50  ug  of 
substrate,  200 tA of 0.05 M sodium citrate, pH 4.5, with  1 ~g/t~l taurodeoxycholate, and 
200 #1 of enzyme (0.1  U), and was incubated for 16 h at 37°C. Detergent was removed 
from the products by DEAE-Sephadex column chromatography using chloroform/meth- 
anol/water (30:60:8) (vol/vol) as the eluate.  The products were evaluated by thin-layer 
chromatography and by immunostaining. 
Liposome Preparation.  Liposomes, with or without glycosphingolipids, were prepared 
as follows.  Phosphatidylcholine (3.3  umoles) was dried  in a  tube  with  (0..08  ~moles)  or 
without glycosphingolipid, resuspended in 1 mi of PBS and sonicated for 30 min. Aliquots 
were used in the hemagglutination and rosetting assays. 
Rosetting Antiglobulin  Test.  This test  was employed in parallel  with an agglutination 
assay to assess the binding of the anti-Gal to the various liposome preparations.  The test 
is based on the high affinity between  the  Fc portion of RBC-bound IgG molecules and 
the Fc receptors on the myeloid cell line K562. This interaction leads to the formation of 
erythrocyte-antibody (EA) rosettes. The proportion of the K562 cells forming EA rosettes 
is related to the amount of the RBC-bound antibody molecules (14). Washed RRBC (0.1 
ml ofa 1% solution) were mixed with an equal volume of antibody solution, and incubated 
for 30 min at 37°C. The RBC were washed twice and resuspended in 0.1  ml of rabbit 
anti-IgG (Ortho Immunodiagnostics). The suspension was incubated for 30 rain at 24°C 
and the  RBC were washed twice. The washed  RBC were mixed with  0.1  ml K562 cell 
suspension in PBS (10 6 cells/ml), spun for 5 min at 200 g, and incubated for 120 min at 
4 ° C. The pellet was resuspended, and the percentage of EA rosettes was determined with 
a hemocytometer. 
Hemagglutination  Assay and Inhibition  by Carbohydrates.  Hemagglutination activity of 
the isolated anti-Gal was titrated  by mixing twofold serial dilutions of the antibody with 
an equal volume of 0.5% RRBC suspension in the wells of a microtiter tray. The diluent 
was  PBS,  pH  7.4.  Agglutination  was  evaluated  after  the  RBC  had  settled  at  room 
temperature  for 2 h. Titers were expressed as the greatest dilution of antibody solution 
that caused complete agglutination. 
To assess the capacity of a given carbohydrate to inhibit hemagglutination, the antibody 
at  a  titer  of two  agglutinating  units  was  mixed  with  various  concentrations  of the 
carbohydrate in the titration wells. After a  30 min incubation of the mixture at 37°C, a 
0.5% RRBC suspension was added, and agglutination was determined as described above. 
Binding of the Bandeiraea  simplicifolia (BS) Lectin to RRBC Glycosphingolipids.  The BS 
lectin is known to bind to various glycoconjugates bearing terminal Galal --~ 3Gal residues, 
including human B blood type antigen, calf and murine thyroglobulin, and murine laminin 
(15,  16).  The lectin (Vector Laboratories, San Francisco, CA) was radiolabeled with  125I 
by  Bolton-Hunter  reagent  (New  England  Nuclear,  Boston,  MA).  The  specific activity 
obtained was 106 cpm/tsg. The labeled lectin (1 #g/ml) was used to stain glycosphingolipids 
separated on aluminum-backed TLC plates.  The plates were coated with plastic,  soaked 
with buffer and the labeled  lectin, and washed, and an autoradiograph  was prepared as 
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F~CURE  1.  Thin-layer  chromatogram  of glycosphingolipids immunostained  with  anti-Gal. 
Total  RRBC neutral glycosphingolipids, orcinol stained (lane  1) and immunostained (lane 2); 
RRBC neutral glycosphingolipids enriched for compounds with more than five sugar residues, 
orcinol stained (lane 3) and  immunostained (lane 5);  the enriched neutral  glycosphingolipid 
fi'action  treated  with  a-galactosidase,  orcinol  stained  (lane  4)  and  immunostained (lane  6); 
human blood group B glycosphingolipid, orcinol stained (lane 7) and immunostained (lane 8); 
1251-BS lectin binding to total RRBC neutral glycosphingolipids (lane 9). 
Results 
Specific  Binding  of the  Natural  Anti-Gal  to  CPH  on  RRBC.  The  two  major 
glycosphingolipids in  RRBC membranes are ceramide  trihexoside  (CTH),  with 
a nonreducing terminal a 1 ~  4 galactose, and CPH, with a nonreducing terminal 
al  ~  3 galactose (8).  In view of the observed anti-o~-galactosyl  specificity of the 
natural  anti-Gal  binding  to  RRBC,  we studied  the possibility that  these  glyco- 
sphingolipids may represent the anti-Gal binding site on the RRBC. Giycosphin- 
golipids were isolated from RRBC and evaluated in several assays for their ability 
to bind anti-Gal antibody. Fig.  1 shows thin-layer chromatograms of the neutral 
glycosphingolipids of RRBC, eitber stained with orcinol (lane  1) to reveal all the 
glycosphingolipids,  or immunostained  with anti-Gal  (lane  2).  A  number  of gly- 
cosphingolipids were found in the RRBC preparation, and the major components 
chromatographed at the same position as standard glycosphingolipids containing 
three and five sugar residues. These compounds have been previously character- 
ized  (8)  as  RRBC CTH  and  CPH  (Table  I).  HPLC  fractionation  of the  total 
neutral glycosphingolipid fraction revealed a multitude of components, including 
glycosphingolipids with  more than  five sugar residues.  Some of these probably 
correspond  to  complex  glycosphingolipids  recently  characterized  (17,  18)  as 
structures  containing  nonreducing  terminal  al  ~  3  galactose residues.  HPLC 
TABLE  I 
Glycosphingolipid Structures 
Structure  Name 
Gal~l  --~ 4Galfll --* 4Glc~l --~ 1Cer  CTH 
Galc~l  --* 3Gal~l  --~ 4GlcNAc/31 --* 3Gall31  --->  4GIcfll --~ 1Cer  CPH 
Galcd  --* 4Gall31  --* 4GIcNAc/31 --* 3Galfll --~ 4GIcfll ~  1Cer  P1 
Galc~l  ~  3(Fucal  --~ 2)Gal/31  --> 4GIcNAcl31 --> 3Galfll  --~ 4GIcNAc/31 --~  B-antigen 
3Galfll  --~ 4Gic131 --* lCer GALILI ET  AL.  577 
fractions containing CPH and longer-chain  glycosphingolipids were pooled and 
used in some of the subsequent studies. Fig.  1, lane 3 shows a chromatogram  of 
this pooled preparation. 
When these glycosphingolipids were immunostained with anti-Gai, three bands 
were seen on  the  autoradiogram  (Fig.  1,  lanes  2  and  5),  a  major band,  which 
corresponds  in  mobility  to  the  CPH,  and  two  minor  bands,  with  mobilities 
corresponding  to  glycosphingolipids  with  more  than  eight  sugar  residues.  No 
bands  were  found  that  corresponded  to  CTH  or  any  other  orcinol-positive 
components with less than five sugar residues. Other standard glycosphingolipids 
with terminal galactose residues, including iactosylceramide and neolactotetrao- 
sylceramide were also tested by immunostaining,  and gave negative results (not 
shown). Finally, a human blood group B-active glycosphingolipid (Table I) was 
tested as an antigen  for anti-Gal,  but this compound also gave negative results 
(Fig.  1, lane 7, orcinol strain; lane 8, immunostain).  Therefore, it appears that a 
nonreducing  terminal  a l  ~  3  galactose is  required  for anti-Gal  binding,  and 
that the presence of a branched fucose on the B-antigen blocks anti-Gal binding. 
As a control for nonspecific binding in the immunostaining assay, melibiose (0.2 
M) was added  to the anti-Gal  used  for immunostaining.  No radioactive bands 
were detected on the autoradiograph  of the thin-layer plate under these condi- 
tions, indicating that the binding of the antibody to CPH is a specific antibody- 
antigen reaction. 
The removal of the nonreducing  terminal  galactose residue from the RRBC 
neutral glycosphingolipids was studied for its effect on anti-Gal binding.  Fig.  1, 
lane  6  shows that,  after  treatment  of CPH  with  Ficin  a-galactosidase,  no  im- 
munostaining occurred. The corresponding orcinol-stained chromatogram (Fig. 
1, lane 4) shows that the CPH had been converted to a compound that cochro- 
matographs  with  neolactotetraosylceramide.  Therefore,  conversion  of RRBC 
ceramide pentasaccharide by a-galactosidase to a ceramide tetrasaccharide bear- 
ing a terminal ~-galactose (see Table I) abolishes anti-Gal binding. Similarly, the 
anti-Gal binding to longer-chain  neutral glycosphingolipids was eliminated by a- 
galactosidase treatment.  These results further substantiate  the requirement  for 
a  nonreducing  a-galactose  residue  for anti-Gal  binding,  and  indicate  that  the 
neutral glycosphingolipids that are recognized by anti-Gal have a similar epitope. 
The  specificity of anti-Gal  binding  to  RRBC neutral  glycosphingolipids was 
further analyzed by using liposomes containing the purified CPH and CTH. The 
anti-Gal  IgG preparation  used in this study agglutinated  RRBC up to a titer of 
1:400.  The  addition  of phosphatidylcholine  (PC)  liposomes or  PC-CTH  lipo- 
somes did not reduce the capacity of the anti-Gal  to agglutinate  RRBC (Table 
II). However, liposomes of PC-CPH inhibited  75% of the reactivity of the anti- 
Gal as indicated by a reduction of the titer to 1  : 100. The specific binding of the 
anti-Gal  to  the  CPH on  the  liposomes was further  confirmed  by the  sensitive 
rosetting  antiglobulin  test.  The  agglutination  assay  gave  an  anti-Gal  titer  of 
1:400,  whereas, by the rosetting antiglobulin  tests, the antibodies bound to the 
RRBC were detected up to a titer of 1:3,200 of the anti-Gal (Fig. 2). No reduction 
in the proportion of rosettes at any of the anti-Gal dilutions was observed when 
PC liposomes or  PC-CTH  liposomes were used.  However, the addition  of the 578  HUMAN  NATURAL  ANTI-a-GALACTOSYL  IgG 
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FIGURE  2.  Binding of anti-Gal to liposome containing glycosphingolipids, as determined by 
inhibition of rosetting antiglobulin  test.  Rosette formation following incubation  of anti-Gal 
with: PBS control (A); PC liposomes (~7); PC CTH liposomes ((3); PC CPH liposomes (F]). 
PC-CPH liposomes decreased the reactivity of the anti-Gal in this assay to a titer 
of 1:400 (90% inhibition of reactivity). 
Inhibition of Anti-Gal Binding to RRBC by Various Galactosyl-containing Oligosac- 
charides.  In accord with our previous studies (5), the agglutination of RRBC by 
anti-Gal is readily inhibited by o~-methyl galactoside and melibiose, but not by/3- 
methyl galactoside or lactose (Table III). The saccharide Galc~l --~ 3Gal inhibited 
the agglutination at a  lower concentration (0.3  mM) than melibiose (Galc~l 
6Glc). Saccharides containing the Galo~l ~  4Gal structure failed to inhibit the 
observed  hemagglutination when they were added at a  concentration 33-fold 
greater than that of the Galal ~  3Gal disaccharide. 
Specific  Binding  of the  BS  Lectin  to  CPH.  In  view of the  reported  (15,  16) 
Galal ~  3 specificity of the BS lectin we wished to compare its binding to RRBC 
glycosphingolipids with that of anti-Gal. As shown in Fig. 1, lane 9, 125I-B8 lectin 
appears to bind to the same component in the RRBC glycosphingolipid mixture 
as anti-Gal. However, in hemagglutination inhibition studies using oligosaccha- 
rides of known structures, differences were found between the BS  lectin and 
anti-Gal.  In  addition  to  the  oligosaccharides that  inhibited anti-Gal-mediated 
hemagglutination of RRBC (Table II), BS lectin-mediated hemagglutination was 
effectively inhibited by GalNAc, and Galal ~  4Gal (not shown). 
TABLE  II 
Inhibition of Anti-Gal-mediated Agglutination of RRBC by Liposomes Containing Glycolipids 
Liposome 
Anti-Gal dilution 
1:50  1:100  1:200  1:400  1:800 
No liposomes 
Liposome alone 
Liposome +  CTH  Galal  ~  4Gal 
Liposome +  CPH Galal  ~  3Gal 
+*  +  +  + 
+  +  +  + 
+  +  +  + 
+  +  -  _ 
* +, agglutination; -, no agglutination. GALIL1  ET  AL.  579 
TABLE  III 
Inhibition of Anti-Gal-mediated Agglutination of RRBC by Various Galactosyl-containing 
Oligosaccharides 
Carbohydrate 
Carbohydrate  concentration 
10  5  2.5  1.25  0.6  0.3  0.15 
mM 
a-Methyl  Gal  -*  -  -  +  +  +  + 
/3-Methyl Gal  +  +  +  +  +  +  + 
Galc~l ~  6Glc (melibiose)  ....  +  +  + 
Gal~l  --o 4Glc (lactose)  +  +  +  +  +  +  + 
Galal  --o 3Gal  ......  + 
Galal  ---, 4Gal  +  +  +  +  +  +  + 
Galal  --o 4Gal~l  --o 4GIcNAc  +  +  +  +  +  +  + 
(P1 substance) 
*  +, agglutination;  -,  no agglutination. 
Discussion 
Most of the antigenic structures recognized by the known natural antibodies 
in human serum have not been characterized. Low titers of IgG antibodies to 
various evolutionarily conserved proteins, including actin, myosin, thyroglobulin, 
myoglobin, and band 3  of the red cell membrane have been found in normal 
sera (19, 20). These antibodies display various degrees of crossreactivity, bind to 
epitopes of unknown structures, and are present in quantities of <1  ~g/ml of 
serum. In contrast to other natural antibodies, anti-Gal occurs in high titers and 
quantities (50-100 ug/ml) in every individual tested, and displays a distinct anti- 
a-galactosyl specificity (5). 
In  this study, we have shown that anti-Gal not only recognizes an  a-linked 
galactose nonreducing terminal residue, but also binds specifically to a-galactose 
residues linked 1 ~  3 and not 1 --o 4 to a penultimate galactose. Immunostaining 
and hemagglutination studies with the RRBC membrane glycosphingolipids  have 
indicated that the anti-Gal does not interact with Galal ~  4Gal residue that is 
characteristic  of CTH,  but  binds  specifically to  Galal  ~  3Gal,  which  is  the 
terminal disaccharide of CPH. This binding was eliminated by removal of the 
terminal galactosyl group by a-galactosidase. The specific interaction of the anti- 
Gal with  Galal  --o  3Gal  structures was further demonstrated by the  use of a 
Galal ~  3Gal oligosaccharide, which inhibited the agglutination of RRBC by 
the antibody. The lack of interaction between anti-Gal and B-antigen, either on 
red cells (5) or in its purified form, as demonstrated herein, implies that the a 1 
2  fucose linked to the penultimate galactose prevents anti-Gal binding.The 
RRBC CPH has long been considered (8, 21) to be serologically related to the B 
antigen in the human ABO system, since both molecules bear terminal Galal --o 
3Gal~3 residues. However, Betteridge and Watkins (21) have recently shown that 
the enzyme that catalylzes the transfer of the terminal a-galactosyl residue to 
form the rabbit CPH molecule is different from the enzyme transferring galactose 
to produce the B antigen molecule present in rabbit stomach mucosa (21).  Based 
on these enzyme studies and observations that RRBC fail to completely absorb 
the anti-B-agglutinins from many human group A  sera,  these authors recom- 580  HUMAN NATURAL ANTI-c~-GALACTOSYL IgG 
mended the reevaluation of the concept that CPH is a B-related substance (21). 
The lack of  binding ofanti-Gal to the B-antigen, as demonstrated herein, supports 
this recommendation. 
The Galal  ~  3 specificity of the natural anti-Gal seems to partially parallel 
that of the lectin BS, which was previously found by Eckhardt and Goldstein (15) 
to bind to glycoconjuates bearing Galal ---> 3 residues on murine Ehrlich ascites 
cells and basement membrane in various tissues of the mouse, and by Spiro and 
Bhoyroo (16) to interact with Gala l  ---* 3 residues on calf and murine thyroglob- 
ulin molecules. Both the antibody and the lectin bind to CPH and not to CTH 
from RRBC.  However, unlike anti-Gal, BS  lectin readily binds to the B blood 
group antigen (15).  Thus, the BS lectin displays a broader specificity than anti- 
Gal. It should be noted that, whereas BS lectin agglutinates RRBC at a concen- 
tration as  low as  0.02  #g/ml,  3,000  times as  much (60  #g/ml) of the lectin is 
needed to agglutinate human  B-type red  cells  (our  unpublished observation). 
This suggests that the  fucosylation of the penultimate galactosyl, which com- 
pletely prevents the interaction with the anti-Gal, greatly reduces, but does not 
completely eliminate the binding capacity of the BS lectin to the glycosphingo- 
lipid. 
Previous  studies  (5-7)  have  suggested that anti-Gal  may play a  role  in  the 
removal of normal senescent and pathological human red cells from the circula- 
tion. Only  1%  of normal human red cells  were found to bind anti-Gal. These 
cells  had  the  highest density, and  are  thought to  be  the  senescent red  cells. 
Moreover, much greater proportions of thalassemic and sickle cells interact with 
anti-Gal. On the basis  of these observations, it was postulated that in situ anti- 
Gal binding to human red cells  involves the de novo exposure of a glycoconju- 
gate(s) bearing a terminal oMinked galactose. Only three glycoconjugates with a 
nonreducing terminal 0Minked galactose are known to be present on human red 
cells,  CTH, Px, and B antigen. The results obtained herein suggest that neither 
CTH nor Pj, which are abundant on human red cells,  serve as the binding site 
for anti-Gal, since both have Galo~l ----> 4Gal terminal disaccharides (22). Further- 
more, anti-Gal does not bind to the B antigen. 
The distribution of the Galal  ---> 3Gal structure and of the anti-Gal natural 
antibodies in various mammals is of special interest. The anti-Gal antibodies were 
found in baboons, in addition to man, but not in mice, rats,  guinea pigs, and, 
evidently, rabbits (5). However, whereas Galal ---> 3Gal structures were found 
to be abundant in mouse, rabbit, and calf glycoconjugates, no such structures, 
except for the fucosylated B antigen, have been found thus far in human tissues 
using the BS lectin (23).  Hence, it may be possible that, with the evolutionary 
need  for a  permanent production  of anti-Gal  in  primates  and  man,  perhaps 
toward some gastrointestinal or pulmonary bacteria, a concomitant suppression 
of the synthesis of Galal  ~  3Gal glycoconjugates occurred. This possibility is 
supported  by studies that  have shown  that bacterial  lipopolysaccharides from 
Salmonella and E.  coli contain nonreducing terminal 0~1  ---> 3 galactose (24, 25). 
The  recently reported  findings (5-7,  26)  on  anti-Gal  binding to  a-galactosyl 
residues exposed on normal human senescent red cells,  thalassemic, and sickle 
red cells implies that the suppression of Galo~l ----> 3Gal glycoconjugate synthesis 
in man is not absolute. The characterization of these molecules in human red GALILI  ET  AL.  581 
cells is currently under study.  Finally, in view of the high amounts of the anti- 
Gal in human serum, the identification of such glycoconjugates on other tissues 
might imply a possible role for this unique natural antibody in the development 
of various autoimmune states. 
Summary 
A natural lgG antibody (anti-Gal) with ~-galactosyl binding specificity has been 
found in large amounts (0.5-1.0% of serum IgG) in all individuals tested. It has 
been purified by affinity chromatography on a  column of melibiose-Sepharose. 
In addition to its affinity for normal and pathological senescent human red cells, 
the antibody readily interacts with rabbit red blood cell (RRBC) glycolipids with 
~-galactosyl terminal residues.  Two types (glycosidic linkages of 1 --+ 3 vs.  1 --+ 
4) of rabbit red cells glycolipids with terminal ~-galactosyl residues were tested 
for  antibody  binding.  The  antibody  specifically  bound  to  glycolipids  with 
Galal  --+ 3 terminal residues, and treatment of these glycolipids with ~-galacto- 
sidase abolished binding.  Hemagglutination inhibition  studies with oligosaccha- 
rides  of known  structure  also  showed  that  the  antibody  binds  specifically  to 
glycoconjugates with  an  0el  --+  3  terminal  galactose  residue.  Anti-Gal  did  not 
bind to a human B-active glycolipid, indicating that fucose-linked ~1 ~  2 to the 
penultimate  galactose  prevents  anti-Gal  binding.  The  anti-Gal  specificity  for 
RRBC  glycolipids  also  paralleled  that  of  the  0~-galactosyl-specific  Bandeiraea 
simplicifolia  lectin. The possible reasons for the occurrence of this unique anti- 
body in human serum are discussed. 
Received for publication  9 April 1985. 
References 
1.  Kabat,  E.  A.  1976.  Structural concepts in immunochemistry. Holt,  Rinehart, and 
Winston, New York. 174-189. 
2.  Watkins, W. M.  1966. Blood group substances. Science (Wash. DC).  152:172. 
3.  Springer, G. F., P. R. Desai, M. S. Murphy, H. Tegtmeyer, and E. F. Scanlon. 1979. 
Human carcinoma associated precursor antigens of the blood group MN system and 
the host immune response to them. Pro& Allergy. 26:42. 
4.  Bray, J, R. U. Lumneux, and T. A. McPherson. 1981. Use of a synthetic hapten in 
the  demonstration  of the  Thomsen-Friedenreich (T)  antigen  on  neuraminidase- 
treated human red blood cells and lymphocytes.  J. lmmunol.  126:1966. 
5.  Galili,  U.,  E.  A.  Rachmilewitz, A.  Peleg, and I. Flechner.  1984.  A  unique natural 
human IgG antibody with anti-a-galactosyl specificity.  J. Exp. Med.  160:1519. 
6.  Galili,  U., A. Korkesh, I. Kahane, and E. A. Rachmilewitz. 1983. Demonstration of 
a natural antigalactosyl IgG antibody on thalassemic red blood cells. Blood. 61:1258. 
7.  Galili, U., M. Clark, N. Mohandas, E. A. Rachmilewitz, and S. B. Shohet. 1984. The 
natural anti-c~-galactosyl IgG on red cells in sickle cell disease.  Blood. 64(Suppl.): 102. 
8.  Eto, T., Y. Ichikawa, K. Nishimura, S. Ando, and T. Yamakawa. 1968. Chemistry of 
lipid of the posthemolytic residue or stroma of erythrocytes. XVI.  Occurrence of 
ceramide  pentasaccharide  in  the  membrane  of erythrocytes and  reticulocytes of 
rabbit.J. Biochem. (Tokyo). 64:205. 
9.  Dodge, J. T., C.  Mitchel, and D. J. Hanahan.  1963. The preparation and chemical 
characteristics  of hemoglobin-free ghosts  of human  erythrocytes. Arch.  Biochem. 
Biophys. 100:119. 582  HUMAN NATURAL  ANTI-~-GALACTOSYL IgG 
10.  Lee, W. M. F., M. A. Westrick and B. A. Macher.  1982.  Neutral glycosphingolipids 
of human acute leukemias. J. Biol. Chem. 257:10090. 
11.  Ledeen,  R.  W.,  R.  K.  Yu,  and  L.  F.  Eng.  1973.  Gangliosides of human  myelin: 
sialosylgalactosylceramide (G7) as a major component. J. Neurochem.  21:829. 
12.  Watanabe, K., and Y. Arao. 1981. A new solvent system for the separation of neutral 
glycosphingolipids. J. Lipid Res.  22:1020. 
13.  Li, Y., and S. Li.  1972. ~-Galactosidase  from figs. Methods Enzymol.  28:714. 
14.  Galili,  U.,  N.  Manny, and G.  Izak.  1981.  EA rosette formation: a simple  means to 
increase sensitivity  of antiglobulin test in patients with anti-red cell antibodies. Brit. 
J. Haematol.  47:227. 
15.  Eckhardt, A. E., and I. J. Goldstein.  1983. Isolation and characterization of a family 
of c~-galactosyl  containing glycoproteins from Ebrlich-ascites  tumor cells. Biochemistry. 
22:5290. 
16.  Spiro,  R.  G.,  and  V.  D.  Bhoyroo.  1984.  Occurrence of C~-D-galactosyl residues  in 
thyroglobulin from several  species.  Localization in the saccharide complex carbohy- 
drate units. J. Biol.  Chem. 259:9858. 
17.  Dabrowski,  J.,  and  P.  Hanfland.  1982.  Structural  determination  of a  ceramide 
pentadecosaccharide by two-dimensional J-resolved and J-correlated NMR spectros- 
copy. FEBS (Fed. Eur. Biochem. Soc.) Lett.  142:138. 
18.  Hanfland, P.,  U. Dabrowski, M. Kordowski, J. Peter-Katalinic, J. Dabrowski, and H. 
Egge.  1983.  Purification and structural elucidation of three different blood-group- 
B-  and  I-  or  i-active  glycosphingolipids from  rabbit  erythrocyte  membranes.  In 
Glycoconjugates.  M.  A.  Chester,  D.  Heinegard,  A.  Lundblad,  and  S.  Svensson, 
editors. Rahms, Lund, Sweden. 413-414. 
19.  Guilbert,  B.,  G.  Dighiero, and S.  Avrameas.  1982.  Naturally occurring antibodies 
against nine common antigens in human sera.  I. Detection, isolation,  and character- 
ization. J. Immunol.  128:2779. 
20.  Lutz, H. U., R. Flepp, and G. Stringnaro-Wipf. 1984.  Naturally occurring antibodies 
to exoplasmic and cryptic regions of band 3 protein, the major integral membrane 
protein of human red blood cells. J. Immunol.  133:2610. 
21.  Betteridge, A., and W. M. Watkins.  1983. Two c~-3-D-galactosyl  transferases in rabbit 
stomach mucosa with different acceptor substrate specificities. Eur.J. Biochem. 132:29. 
22.  Marcus, D. M., S. K. Kundu, and A. Suzuki.  1981.  The P blood group system: recent 
progress in immunochemistry and genetics.  Semin. Haematol.  18:63. 
23.  Peters, B. P., and I.J. Goldstein.  1979. The use of fluorescein-conjugated Bandeiraea 
simplicifolia  by isolectin  as a histochemical reagent for the detection of a-galactopyr- 
anosyl groups. Exp. Cell Res.  120:321. 
24.  Luderitz, O., D. A. R. Simmons, and O. Westphal.  1965. The immunochemistry of 
Salmonella chemotype VI O-antigens. Biochem. J. 97:820. 
25.  Springer,  G.  F.  1971.  Blood-group and  forssman  antigenic  determinants  shared 
between microbes and mammalian cells. Prog. Allergy.  15:9. 
26.  Galili, U.,  1. Flechner, A. Knyszynski, D. Danon, and E. A. Rachmilewitz.  1985.  The 
natural  anti-c~-galactosyl IgG on  human  normal  senescent  red  blood cells. Brit. J. 
Haematol.  In press. 